Tenaya Therapeutics Inc — Cash Flow (NASDAQ:TNYA) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities 60.81 M104.42 M102.07 M90.5 M 72.71 M Cash from investing activities 238.56 M83.65 M48.72 M1.13 M 44.31 M Cash from financing activities 208.97 M77.77 M4.05 M47.75 M 50.54 M Free cash flow 35.69 M83.79 M100.83 M89.48 M 71.96 M

Новости

Tenaya получила уведомление от NASDAQ из-за цены акций

Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan

Canaccord снизил целевую цену акций Tenaya Therapeutics до $5

Tenaya Therapeutics stock price target lowered to $5 at Canaccord

H.C. Wainwright снижает целевую цену акций Tenaya Therapeutics до $3

Tenaya Stock Drops After Announcing $60M Equity Offering - Tenaya Therapeutics (NASDAQ:TNYA)

S&P 500 Down 1%; Broadcom Earnings Top Views - Applied Therapeutics (NASDAQ:APLT), Broadcom (NASDAQ:AVGO)

Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - Akanda (NASDAQ:AKAN), Applied Therapeutics (NASDAQ:APLT)

Tenaya Therapeutics размещает публичное предложение акций на $60 млн

Tenaya Therapeutics prices $60 million public offering of stock and warrants

Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript

Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC - Slideshow (NASDAQ:TNYA) 2025-12-11